文献速递神经肿瘤

IDH突变型胶质瘤中的DNA损伤:机制与临床意义

DNA damage in IDH-mutant gliomas: mechanisms and clinical implications.
PubMed 文献 · J Neurooncol · 2022-11-09

本文综述IDH突变影响胶质瘤DNA损伤的关键机制,归纳为基因表达、烷化剂敏感性、同源重组和氧化应激四类,并讨论其与放疗、烷化剂及新型基因毒性药物的临床试验关联。临床前与临床数据提示IDH突变通过不同机制改变DNA损伤感知与修复通路,未来需深入研究以转化为治疗获益。

要点

  • IDH突变对DNA损伤的影响主要归为基因表达、烷化剂敏感性、同源重组和氧化应激四类。
  • 突变IDH及其致癌代谢物(R)-2HG影响上述各类DNA损伤机制。
  • 正在开展的临床试验将放疗和烷化剂等标准治疗与针对IDH突变胶质瘤发挥基因毒性应激的新药联合。

核心结论

  • 越来越多的临床前和临床数据提示,IDH突变通过不同机制改变DNA损伤感知与修复通路。
  • 未来研究需加深对这些过程的理解并提供更多机制见解,以用于治疗获益。

研究设计与样本

  • 本文为综述,对同行评议文献进行了全面回顾。

主要发现

  • 突变IDH对DNA损伤的影响主要归为四类:基因表达、烷化剂敏感性、同源重组和氧化应激。
  • 从机制角度讨论了突变IDH和致癌代谢物(R)-2HG如何影响上述每一类DNA损伤。
  • 结合正在进行的临床试验对上述机制进行了情境化讨论。
  • 正在开展的研究将放疗和烷化剂等当前标准治疗与新型治疗药物联合,后者在IDH突变胶质瘤中特异性发挥基因毒性应激。
  • 讨论了该领域关键未解问题和新兴数据,这些对理解胶质瘤生物学和开发新脑肿瘤疗法具有重要意义。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Since the discovery of IDH mutations in glioma over a decade ago, significant progress has been made in determining how these mutations affect epigenetic, transcriptomic, and metabolic programs in brain tumor cells. In this article, we summarize current understanding of how IDH mutations influence DNA damage in glioma and discuss clinical implications of these findings. METHODS: We performed a thorough review of peer-reviewed publications and provide an overview of key mechanisms by which IDH mutations impact response to DNA damage in gliomas, with an emphasis on clinical implications. RESULTS: The effects of mutant IDH on DNA damage largely fall into four overarching categories: Gene Expression, Sensitivity to Alkylating Agents, Homologous Recombination, and Oxidative Stress. From a mechanistic standpoint, we discuss how mutant IDH and the oncometabolite (R)-2HG affect each of these categories of DNA damage. We also contextualize these mechanisms with respect to ongoing clinical trials. Studies are underway that incorporate current standard-of-care therapies, including radiation and alkylating agents, in addition to novel therapeutic agents that exert genotoxic stress specifically in IDH-mutant gliomas. Lastly, we discuss key unanswered questions and emerging data in this field that have important implications for our understanding of glioma biology and for the development of new brain tumor therapies. CONCLUSION: Mounting preclinical and clinical data suggest that IDH mutations alter DNA damage sensing and repair pathways through distinct mechanisms. Future studies are needed to deepen our understanding of these processes and provide additional mechanistic insights that can be leveraged for therapeutic benefit.

来源:J Neurooncol,查看原文。版权归原作者所有。

引用

  1. Shi DD, Anand S, Abdullah KG, et al. DNA damage in IDH-mutant gliomas: mechanisms and clinical implications. J Neurooncol. 2022. PMID: 36352183. doi:10.1007/s11060-022-04172-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。